Ian Goldlust
Ian Goldlust is currently a medical student in the PhD-to-MD program at Columbia. He joined the Califano Lab in his first year of medical school after completing his PhD at the University of Cambridge as part of a joint program with the NIH. Prior to starting his PhD Ian worked in the Rudd lab at Emory University where he studied a previously unreported translocation syndrome.
His current research focuses on characterizing and targeting residual tumor spheroids in high-grade serous ovarian cancer using high-throughput screening and sequencing.
Mathews Griner LA, Zhang X, Guha R, McKnight C, Goldlust IS, Lal-Nag M, Wilson K, Michael S, Titus S, Shinn P, Thomas CJ, Ferrer M. Large-scale pharmacological profiling of 3D tumor models of cancer cells. Cell Death Dis. 2016 Dec 1;7(12):e2492.
Chen L, Wilson K, Goldlust I, Mott BT, Eastman R, Davis MI, Zhang X, McKnight C, Klumpp-Thomas C, Shinn P, Simmons J, Gormally M, Michael S, Thomas CJ, Ferrer M, Guha R. mQC: a heuristic quality-control metric for high-throughput drug combination screening. Sci Rep. 2016 Nov 24;6:37741.
Di Veroli GY, Fornari C, Goldlust I, Mills G, Koh SB, Bramhall JL, Richards FM, Jodrell DI. An automated fitting procedure and software for dose-response curves with multiphasic features. Sci Rep. 2015 Oct 1;5:14701.
Acquavella N, Clever D, Yu Z, Roelke-Parker M, Palmer DC, Xi L, Pflicke H, Ji Y, Gros A, Hanada K, Goldlust IS, Mehta GU, Klebanoff CA, Crompton JG, Sukumar M, Morrow JJ, Franco Z, Gattinoni L, Liu H, Wang E, Marincola F, Stroncek DF, Lee CC, Raffeld M, Bosenberg MW, Roychoudhuri R, Restifo NP. Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest. Cancer Immunol Res. 2015 Jan;3(1):37-47.
Kim MK, Min DJ, Wright G, Goldlust I, Annunziata CM. Loss of compensatory pro-survival and anti-apoptotic modulator, IKKepsilon, sensitizes ovarian cells to CHEK1 loss through an increased level of p21. Oncotacolumbiarget. 2014 Dec 30;5(24):12788-802.
Hall MD, Telma KA, Chang KE, Lee TD, Madigan JP, Lloyd JR, Goldlust IS, Hoeschele JD, Gottesman MM. Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes. Cancer Res. 2014 Jul 15;74(14):3913-22.
Mathews Griner LA, Guha R, Shinn P, Young RM, Keller JM, Liu D, Goldlust IS, Yasgar A, McKnight C, Boxer MB, Duveau DY, Jiang JK, Michael S, Mierzwa T, Huang W, Walsh MJ, Mott BT, Patel P, Leister W, Maloney DJ, Leclair CA, Rai G, Jadhav A, Peyser BD, Austin CP, Martin SE, Simeonov A, Ferrer M, Staudt LM, Thomas CJ. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2349-54.
Goldlust IS, Hermetz KE, Catalano LM, Barfield RT, Cozad R, Wynn G, Ozdemir AC, Conneely KN, Mulle JG, Dharamrup S, Hegde MR, Kim KH, Angle B, Colley A, Webb AE, Thorland EC, Ellison JW, Rosenfeld JA, Ballif BC, Shaffer LG, Demmer LA; Unique Rare Chromosome Disorder Support Group., Rudd MK. Mouse model implicates GNB3 duplication in a childhood obesity syndrome. Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):14990-4.
Wang T, Wu H, Li Y, Szulwach KE, Lin L, Li X, Chen IP, Goldlust IS, Chamberlain SJ, Dodd A, Gong H, Ananiev G, Han JW, Yoon YS, Rudd MK, Yu M, Song CX, He C, Chang Q, Warren ST, Jin P. Subtelomeric hotspots of aberrant 5-hydroxymethylcytosine-mediated epigenetic modifications during reprogramming to pluripotency. Nat Cell Biol. 2013 Jun;15(6):700-11.
Mason-Suares H, Kim W, Grimmett L, Williams ES, Horner VL, Kunig D, Goldlust IS, Wu BL, Shen Y, Miller DT, Martin CL, Rudd MK. Density matters: comparison of array platforms for detection of copy-number variation and copy-neutral abnormalities. Genet Med. 2013 Sep;15(9):706-12.
Topp S, Reynoso CM, Seeliger JC, Goldlust IS, Desai SK, Murat D, Shen A, Puri AW, Komeili A, Bertozzi CR, Scott JR, Gallivan JP. Synthetic riboswitches that induce gene expression in diverse bacterial species. Appl Environ Microbiol. 2010 Dec;76(23):7881-4.
Twitter
Linkedin
Youtube